The complement-mediated binding of soluble antibody/dsDNA immune complexes to human neutrophils.
The complement-mediated binding of soluble antibody/3H-dsDNA immune complexes (prepared in vitro) to human polymorphonuclear leukocytes (PMN) has been investigated quantitatively. Studies with isolated complement components in conjunction with experiments on the binding of these complexes to human red blood cells suggest that the binding to both cell types is mediated predominantly by CR1 (C4b-C3b) receptors but that CR3 (iC3b or C3d-g) receptors may play a role in binding to PMN but probably not to RBC. Our results also indicate that under the standard conditions of these assays (37 degrees C, 20 to 40 min incubations) there is no significant internalization of the soluble antibody/dsDNA immune complexes after they are bound by the PMN.
D000936:Antigen-Antibody Complex / Q000378:metabolism*; D003175:Complement C2 / Q000378:metabolism; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D004247:DNA / Q000276:immunology*; D004912:Erythrocytes / Q000378:metabolism; D005033:Ethylmaleimide / Q000494:pharmacology; D006801:Humans; D007460:Iodoacetamide / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D009504:Neutrophils / Q000378:metabolism*; D010587:Phagocytosis; D011951:Receptors, Complement / Q000032:analysis* / Q000187:drug effects
D000936:Antigen-Antibody Complex; D003175:Complement C2; D003176:Complement C3; D003181:Complement C4; D011951:Receptors, Complement; D004247:DNA; D005033:Ethylmaleimide; D007460:Iodoacetamide